ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
This study is testing a special inhaled antibiotic called ALIS to see if it helps improve breathing symptoms for adults with a stubborn type of lung infection called MAC. Researchers want to find out if adding this inhaled medicine to standard antibiotic pills works better than standard pills alone.
You might be able to join if you are an adult aged 18 or older with a newly diagnosed MAC lung infection and have not yet started antibiotics for it. Participants must also be willing to follow all study instructions and use birth control if they can have children.
Participants will take a combination of antibiotic medications, which may include the inhaled study drug ALIS or a dummy treatment that looks like it, along with standard antibiotic pills. You will also have check-ups to track your respiratory symptoms and overall lung health over several months.
This study has multiple locations, including clinics in Alabama and California within the United States. Please note that this particular study has already been completed.
- 1Tests an inhaled antibiotic called ALIS for MAC lung infections.
- 2Compares the inhaled medicine plus standard pills against a dummy treatment plus standard pills.
- 3The study has finished and evaluated participant-reported breathing symptoms at Month 13.
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.